Introduction
Over 40 million people worldwide are infected by HIV-1 [1] , and although HIV-1 is most well known for its devastating effects on the immune system and the resulting AIDS, it can involve any level of the neuraxis [2] . In this review, we will focus on updates related to HIV-associated neurocognitive disorders (HAND). Despite the success of combination antiretroviral therapy (cART) in controlling HIV infection as evident by viral loads decreased to undetectable levels and increasing CD4 count back to the normal level, and despite a decrease in the risk of opportunistic infections and mortality, HAND have continued to affect HIV-infected populations [3••] . Neurocognitive impairment even in the milder forms not only has profound socioeconomic consequences from the effects on activities of daily living and the impact on employability, but may also have important consequences for the ability to control this pandemic. These individuals may have difficulty complying with taking medications [4] and keeping physician appointments, may suffer from psychiatric manifestations, may have difficulty in using preventive measures for viral transmission, and may be more vulnerable to sexual abuse. Certainly, the survival rate of patients with HAND is much lower than that of HIV-infected individuals without HAND [5] . Thus, clearly our hope of eradicating this virus or controlling its spread cannot be realized unless we pay close attention to the neurocognitive consequences of the infection and develop ways of effectively treating it.
Changes in Terminology
Many synonymous terms have been used in the past to describe the neurocognitive decline associated with HIV infection, including "AIDS dementia complex," "HIV dementia," "HIVencephalopathy," "minor cognitive motor disorder," and "HIV-associated dementia complex." The term "HIV encephalitis," however, is used for the description of the pathological features of multinucleated giant cell encephalitis with HIV identified in the brain [6] . As the severe forms of neurocognitive impairment such as dementia are seldom seen in patients compliant with cART, current nosology has changed to identify individuals with milder forms of dysfunction. This requires the use of detailed neuropsychological tests and divides HAND into three categories: HIV-associated asymptomatic neurocognitive impairment (ANI), HIVassociated mild neurocognitive disorder (MND), and HIVassociated dementia (HAD) [7] . This categorization recognizes the importance of using demographically appropriate means for comparison, as well as the possible contribution from confounding conditions such as aging, depression, drug abuse, opportunistic CNS disease, and co-infection with hepatitis C virus. Conventional bedside cognitive testing using instruments such as the Mini-Mental State Examination and the HIV Dementia Scale, which were adequate as a screening tool for patients with dementia, is not reliable for revealing impairment in most patients with HAND. Comprehensive neuropsychological testing with the application of appropriate normative corrections is much more sensitive and specific. One drawback of the current system is that it does not take into account psychiatric manifestations of HIV infection such as depression and psychosis.
Changing Pattern of Clinical Features in the Post-cART Era
HAND typically present as a subcortical dementia with cognitive, behavioral, and motor decline over weeks or months, which interferes with activities of daily living and cannot be explained by another preexisting neurological disease, severe substance abuse, or another cause of dementia. Since the cART era, the cumulative risk of developing HAND during the course of the infection has reduced, but because of the longer survival and the subsequently increasing age of the infected individuals, the prevalence has continued to rise [3••] . In 2007, the category of ANI was added to HAND. ANI refers to individuals who score one standard deviation below the mean on at least two areas of a standardized neuropsychological test; however, that impairment on testing is not causing an observable functional impairment. These patients may go on to develop symptomatic impairment in the form of MND or HAD, but the time course of cognitive change in HIV is not predictable or linear in many cases. Even with consistent cART, cognitive performance may fluctuate over time, making diagnosis more difficult; in some cases complete recovery occurs after initiation of cART [8] . MND describes an individual who demonstrates impairment on neuropsychological testing as just described for ANI but who also demonstrates some type of mild impairment in daily functioning. Such a patient is likely to be able to continue working, although at a reduced level of productivity or efficiency. Movement disorders, such as gait disturbance, tremor, and impairment of fine manual dexterity, may be present [9] . HAD refers to a person showing marked impairment on neuropsychological testing and in daily functioning.
Disorientation, mood disturbances, psychomotor slowing, and a decrease in attention, memory, and visuoconstructive coordination are part of the clinical picture. Motor symptoms are often mild and may consist of a slowing of repetitive movements or balance problems. Absence of focal cortical signs such as apraxias, agnosias, or aphasias assists in distinguishing the condition from cortical dementia such as Alzheimer's disease. Patients with HAD have difficulty learning new information, such as word lists, but they do not show the rapid forgetting that is commonly seen in Alzheimer's disease.
The large National Institute of Mental Health CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) cohort study used standardized neuropsychological tests to evaluate 857 patients from 1988 to 1995, and 937 patients from 2000 to 2007. Between the pre-antiretroviral therapy (ART) and ART eras, fewer patients performed poorly in verbal fluency (e.g., number of animals named in a timed setting), speed of information processing (digit vigilance time), and motor domains (grooved pegboard test), whereas more patients showed deficits in learning and memory (story memory test) and executive functioning (Wisconsin card-sorting test). The domains of recall, working memory, and attention were stable across the two time periods [10] . This shift in the cognitive domains most affected in patients with HIV infection has important implications for trials of adjunctive therapy, such as antioxidants or neuroprotective agents, in determining which cognitive tests to study. Whether these data reveal a greater degree of cortical impairment, rather than subcortical disease, in HAND in the ART era will require neuroimaging and neuropathological correlation.
In the cART era, some patients may also develop a progressive subacute encephalitis called CNS immune reconstitution inflammatory syndrome (IRIS). This inflammation is driven by CD8 + T cells and presents with cognitive decline, seizures, and eventually coma and death. Early recognition and treatment with corticosteroids can reverse the process (reviewed in [11•] ).
Laboratory Investigations
Magnetic resonance imaging of the brain may show progressive cortical atrophy and diffuse while matter changes particularly in advanced stages of the disease (Fig. 1) . Magnetic resonance spectroscopy may show elevation of the level of myoinositol suggestive of inflammation or glial cell activation and a decrease in the level of N -acetylaspartate suggestive of neuronal injury. The electroencephalogram does not show any specific changes, although generalized slowing may be seen. Occasionally seizure activity may be detected, particularly in patients with IRIS. CSF may be normal or may have mild pleocytosis and slightly elevated protein levels. The levels of inflammatory markers such as cytokines and chemokines (which are available only in research laboratories) are often elevated in the CSF. In the untreated patient the markers suggest macrophage activation, whereas in individuals treated with antiretroviral drugs, the profile suggests T-cell activation instead [9] .
Evolution of Risk Factors for HAND
Interestingly, even in the pre-cART era, nearly 50 % of individuals with HIV infection did not develop neurocognitive impairment, suggesting that host or viral genetic factors may play a role [3••] . However, host genetic factors have not been extensively studied. Polymorphisms in apolipoprotein, cytokine, and chemokine pathways and innate immune responses have been implicated in the progression of neurocognitive dysfunction of HIV-infected individuals [12] [13] [14] . Studies investigating as genome-wide associations and high-throughput single nucleotide polymorphisms are needed to identify the critical genes involved in HIV neuropathogenesis. This will also allow better clinical trial design and may have implications for other neurological diseases.
In recent years, several comorbidities have been identified as important risk factors for HAND. These include drug abuse; however, since most patients are polydrug abusers and the types of drugs used and the frequency of drug use may be quite variable within a single individual and among patient groups, studying their effects in conjunction to HIV infection in human populations has been challenging [15] . In individuals treated with cART, a metabolic syndrome has been recognized, a prominent feature of which is dyslipidemia that may lead to vascular disease [16] [17] [18] [19] . Microvascular disease can also result in neurocognitive impairment, but the pathophysiological features and treatment would be quite different from those directly due to HIV infection. Aging is another risk factor that leads to increased accumulation of amyloid in the brain at a much more rapid pace compared with the pace in uninfected populations [20, 21, 22•] . The incidence of HAND in older individuals (older than 50 years) is much greater [23] [24] [25] . Hepatitis C infection has also been implicated in causing neurocognitive effects [26] [27] [28] . Hepatitis C infection is a frequent co-infection in HIV-infected drug abusers. Thus, the underlying pathophysiological mechanisms of HAND might be quite variable, and HAND should not be considered a single entity (Fig. 2) .
Neuropathogenesis
The neuropathogenesis of HAND has also evolved over the years, shaped in part by the existing co-morbidities, aging of the infected populations, shift in epidemiology to drug-abusing populations, and the effects of cART. Understanding how these variables may impact the neuropathogenesis of HIV infection is critically important since therapeutic approaches may need to be tailored to these different pathophysiological mechanisms.
Recent attention has been diverted to HIV reservoirs in the brain. This renewed enthusiasm stems from the fact that a few patients claim to have been cured of HIV infection, suggesting that it might be possible to purge the virus from its reservoirs. It remains unknown if this includes the elimination of the virus from the brain. Yet important questions have been raised with regard to the timing of viral entry into the brain, the cell types infected, and the ability of the virus to evolve within the brain [29••] .
Although cART is successful in most cases in rapidly reducing HIV RNA to fewer than 50 copies per milliliter, the virus typically rebounds quickly, sometimes as early as within 2 weeks of cessation of therapy. Studies with highly sensitive assays capable of detecting a level as low as one copy per milliliter have revealed that around 80 % of patients continue to have low-level viremia of around three to five copies per milliliter despite having received cART for several years [30, 31] . Such studies have strengthened the belief that latent infections persist in certain cells within the host and that latent viral genomes can be reactivated to produce infectious viral particles that would explain the rebound of the virus. Multiple mechanisms have been proposed as to how lowlevel viral replication may lead to neurocognitive disorders. These include neurotoxicity and glial cell activation by viral proteins such as gp120 and Tat [32] . Once the proviral DNA has been formed and the viral reservoir has been established, antiretroviral drugs do not impact the production of Tat protein.
Tat can be found in the CSF and infiltrating macrophages within the brain in virologically controlled individuals [33] . Tat can also travel along neuronal pathways and thus can have effects far from the site of production [34] . Tat can cause T-cell activation in a nonclassic manner and can thus play a role in the pathophysiological mechanisms of HAND or CNS IRIS [33] . Activated T cells can cause neuronal injury by the extracellular release of granzyme B [35, 36] . The failure to eradicate HIV from its reservoirs in host tissues is one of the major hurdles towards curing HIV infection, and cells in the brain are one such reservoir.
HIV-1 infection compromises the structural integrity of the intestinal tract and can cause leakage of bacteria into the bloodstream. Such microbial translocation results in elevated plasma levels of bacterial lipopolysaccharide (LPS), and in HIV-infected/AIDS patients is associated with increased monocyte activation and dementia. Additionally, it has recently been reported that HAND is associated with higher systemic levels of plasma LPS [37] . The hypothesis is that HIV-1-infected patients with microbial translocation from the gut will have higher plasma LPS levels and thus more systemic immune activation, leading to increased risk of transit of HIVinfected monocytes into end organs, including the CNS [38] . Another study suggests that HIV-1 infection increases the vulnerability of the blood-brain barrier in response to LPS and facilitates the transmigration of peripheral monocytes/ macrophages [39] .
HIV Evolution in the Brain with cART
Following infection, HIV RNA is reverse transcribed into a strand of DNA that can either be integrated into the chromosomal DNA or reside episomally. Integrated viral DNA produces viral products but can be silenced by epigenetic changes, whereas episomal DNA may either be nonfunctional or may be released extracellularly. In one study, the amount of unintegrated HIV DNA in the brain was found to be sixfold to 81-fold that of integrated DNA [40] . The levels of unintegrated DNA did not correlate with the amount of viral antigen in the brain, suggesting that the unintegrated DNA was either latent or dysfunctional. In contrast, in T cells, HIV is predominantly in an integrated state [41] . The high levels of unintegrated DNA suggest that the brain may be an important reservoir for the virus. Another study showed that the presence of unintegrated HIV DNA and HIV proteins in the brain was associated with dementia [42] . Importantly, the viral load in the brain of patients receiving cART for a prolonged period may be very low [43] . Since the brain is devoid of lymphoid cells, the selective pressure on the virus is different from that in other lymphoid organs. The virus evolves in the brain to become more macrophage tropic [44] with unique brain-specific mutations [45] and is functionally different from macrophage-tropic strains derived from the immune system [46] . Similarly, the Tat protein of HIV also evolves in the brain, and although it maintains its HIV activation properties [47] , it may differ in its neurotoxic potential [48] . The brain-specific mutations in the nef gene result in efficient replication in macrophages [49] . Viral sequences derived from brain macrophages and astrocytes show compartmentalization, suggesting cell-specific evolution in the brain [50] . Viral sequencing shows that the meninges contain viruses from both the brain and the peripheral tissues, suggesting that HIV migrates from the brain, and the meninges are an important conduit for viral transport [51] . The effect of ART on evolution of HIV in the brain is not well understood. Poor penetration of antiretroviral drugs across the blood-brain barrier might result in a low frequency of antiretroviral-resistant sequences in the brain and hence cART might drive the compartmentalization of HIV in the brain. It has been found that cART induces a switch in HIV co-receptor use from CCR5 to CXCR4, which appears later in the CNS compartment compared with the periphery [52] . Importantly, even in patients receiving antiretroviral drugs, maximal viral evolution occurs within brain tissues of individuals with dementia compared with individuals without dementia [53] .
Neurodiagnosis of HIV reservoir
The diagnosis of HAND is difficult and relies on recognition of the clinical syndrome and exclusion of alternative diagnoses, rather than on specific laboratory-based findings. With the effort to eliminate viral reservoirs, especially in the brain, imaging techniques for monitoring the viral reservoirs will be critical. Several methods are being devised, such as developing ligands for positron emission tomography using molecular probes, antibodies to the envelope protein, gp120, or antiviral drugs. However, the ability of the probes and antibodies to cross the blood-brain barrier is limited, and if viral loads are low, such techniques may not be sensitive enough; hence, further research along these lines is necessary.
Treatment
Current Approach to the Use of Antiretroviral Drugs for the Treatment of HAND There are two challenges in the treatment of HAND. The first challenge is to prevent HIV replication in the brain. This step in limited by the poor penetrance of cART into the CNS. Macrophages, the primary target of HIV in the brain, require much higher concentrations of antiretroviral drugs for effective control of viral replication than those required by T lymphocytes [54] . Additionally, resistance mutations in the virus can differ between the CSF and plasma, contributing to the potential reservoir of viral replication in the CNS [55] . A CNS penetration-effectiveness index has recently been proposed to guide the choice of antiretroviral drugs in patients with HAND. Each antiretroviral drug is given a score of 1-4 (4 for much above average CNS penetration, 3 for above average, 2 for average, a 1 for below average), and the sum of the individual agents' scores in a combination regimen provides the CNS penetration-effectiveness index score for that regimen. Individual ART agents with scores of 4 include zidovudine, nevirapine, and indinavir/ritonavir [56] .
Eradication of HIV Reservoirs from the Brain
Several strategies are currently being pursued for systematic eradication of the virus:
1. Activation of viral replication in the reservoirs in the presence of cART to prevent the virus from spreading to other cells. Viral proteins produced by these latent reservoirs will be recognized by the immune cells and the reservoir would then be eliminated. Broadly, these include drugs that could modulate epigenetic changes such as histone deacetylase inhibitors or immune activation therapies [57•] . A concern with this strategy is that activation and production of viral products in the brain could lead to an infiltration of cytotoxic T cells. Infiltration of activated lymphocytes in the brain could be injurious to neurons [35] , leading to an encephalitis termed CNS IRIS [58] . Further, similar strategies have failed to eliminate other persistent CNS viral infections such as JC virus and herpesviruses [58] . However, there may be a window of opportunity for eradication of the virus via this strategy before it enters the brain. 2. Immune ablation for elimination of the reservoirs. Owing to the associated toxicity and immune suppression, this is being used only in HIV-infected individuals with leukemia or lymphoma. This approach targets dividing cells; hence, brain cells that are terminally differentiated may not be eliminated. 3. Engineering of HIV-resistant stem cells by creating mutations in the chemokine receptor CCR5 [59] . However, HIV can enter cells using the CXCR4 chemokine receptor; hence, creating additional blocks for viral replication should be considered.
Methods for Enhancing Delivery of cART to the Brain
The selectively permeable blood-brain barrier interferes with the bioavailability of cART in the brain owing to highly efficient drug efflux systems in the brain [60, 61] . However, a recent study showed that further intensification of antiviral therapy with raltegravir, an integrase inhibitor which achieves high CSF concentrations [62] , did not reduce HIV RNA levels in CSF or intrathecal immunoactivation [63] . Owing to the importance of getting antiretroviral drugs into the brain, a number of novel methods for delivery across the blood-brain barrier are being developed. These methods include disruption of the blood-brain barrier, development of nanoparticles with increased blood-brain barrier permeability, and uptake by brain microvascular endothelial cells via adsorptive-mediated transcytosis and cell-mediated delivery [64] . Blood-brain barrier penetrance is dependent on nanoparticle size and shape and protein and lipid coatings [64] . These physical properties affect drug uptake, release, and ingress across the barrier. Recent reports suggest that nanotechnology can improve the delivery of antiretroviral drugs across the blood-brain barrier so as to affect the biodistribution and efficacy for treatment of HIV-1 disease in the brain. These nanoparticles are taken up by monocytes and are sheltered within these cells as they are carried across the blood-brain barrier. The drug is then released to act within the CNS. These cells are great candidates for cellmediated drug delivery to the CNS. Other laboratories have conjugated nanoparticles with Tat, which has an affinity for nuclear transport mechanisms [65] . This results in a nanoparticle that has high CNS penetrability while still bypassing efflux transporters to prolong exposure within the CNS.
Failure of Neuroprotective and Anti-inflammatory Therapies
Since HIV does not infect neurons, but degeneration of the neurons and accompanying glial cell activation is a prominent neuropathological finding in patients with HIV encephalitis, it was thought that neuroprotective and anti-inflammatory strategies should be effective in halting or slowing the progression of HAND. However, despite several carefully conducted phase 2 studies that have targeted excitotoxic pathways, cytokines, and chemokines, none have shown promising effects [66] . However, these failures are not unique to HAND; similar approaches have failed or have shown very modest effects in other neurodegenerative diseases. One interpretation of these findings might be that once the complex cascades of pathways and feedback loops have been initiated, leading to neuronal injury, blocking single molecules or receptors will not be able to protect the neurons. Thus, either a combination therapy targeting multiple pathways or addition of regenerative approaches may be needed.
Conclusion and Future Directions
It is imperative that better understanding of the viral reservoir in the brain be achieved in the ART era. An estimate of the size of the viral reservoir in the brain in vivo will be important, since an immune attack against a large number of cells would be very detrimental. Although eradication of viral reservoirs is a laudable goal, eliminating HIV from the CNS is extremely challenging, and even if this is possible, these measures will not be applicable for the vast majority of HIV-infected individuals. Hence, other measures are needed to prevent the progression of HAND. A focus on controlling the comorbidities is needed, since they can have a major impact on HAND. Further characterization of neuropsychiatric manifestations of HIV infection, particularly depression and psychosis as an underlying comorbidity of HIV infection and as a consequence of HIV infection, is necessary. Host genetic factors that may predispose to such manifestations also need to be studied. Although major advancements in the development of antiretroviral drugs have been achieved, the next generation of drugs needs to target the Tat protein since it may be a critical factor that drives neuroinflammation in these individuals.
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